electroCore (NASDAQ:ECOR) Issues Earnings Results, Beats Expectations By $0.01 EPS

electroCore (NASDAQ:ECOR) issued its quarterly earnings results on Thursday. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.01, FiscalAI reports. electroCore had a negative net margin of 47.46% and a negative return on equity of 447.87%. The business had revenue of $9.24 million during the quarter, compared to the consensus estimate of $9.09 million.

Here are the key takeaways from electroCore’s conference call:

• CEO Dan Goldberger will retire effective April 1, 2026, with CFO Joshua Lev named Interim President and Michael Fox joining as COO in April, creating near-term leadership transition risk despite planned continuity.
• electroCore reported a record Q4 revenue of $9.2 million (up 31% YoY) and full-year 2025 revenue of $32 million (up 27% YoY), beating analyst revenue and EPS estimates.
• The VA channel is the growth engine—200 VA facilities have purchased gammaCore and ~13,400 VA patients received devices (≈2% penetration), and management plans to expand VA sales coverage to drive further adoption.
• Despite revenue gains, the company posted a $14.0 million net loss (vs. $11.9M in 2024), operating expenses rose to ~$40.9M, and cash & equivalents fell to ~$11.6M, highlighting continued burn and funding considerations.
• Consumer and product momentum: Truvaga drove ~$5.4M in sales (93% growth) with ROAS ≈ $2.10, Quell Fibromyalgia contributed $1.5M after the May 2025 acquisition, and management plans a soft launch of Quell Relief (OTC) in H1 2026, which would be incremental to current growth expectations.

electroCore Stock Down 5.1%

Shares of NASDAQ ECOR opened at $6.55 on Friday. The stock has a market capitalization of $52.40 million, a PE ratio of -3.83 and a beta of 0.48. The firm has a fifty day moving average of $6.61 and a 200-day moving average of $5.55. electroCore has a 52-week low of $4.16 and a 52-week high of $8.64.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. raised electroCore to a “strong-buy” rating in a research note on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of electroCore in a research note on Monday, December 29th. HC Wainwright reduced their target price on electroCore from $25.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, January 26th. Finally, Zacks Research lowered electroCore from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 28th. One analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $18.00.

Hedge Funds Weigh In On electroCore

Several hedge funds and other institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new stake in shares of electroCore during the 1st quarter worth about $153,000. NewEdge Advisors LLC raised its holdings in electroCore by 857.9% in the first quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock valued at $1,083,000 after buying an additional 145,047 shares during the period. Jane Street Group LLC lifted its position in electroCore by 114.4% during the first quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock valued at $246,000 after buying an additional 19,599 shares in the last quarter. Two Sigma Investments LP lifted its position in electroCore by 20.8% during the third quarter. Two Sigma Investments LP now owns 24,603 shares of the company’s stock valued at $122,000 after buying an additional 4,231 shares in the last quarter. Finally, DRW Securities LLC purchased a new stake in electroCore during the fourth quarter worth approximately $264,000. 26.74% of the stock is owned by institutional investors and hedge funds.

About electroCore

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.